Login
Related Links
European Union FP6 Integrated Projects
FP6 is the European Community Framework Programme for Research, Technological Development and Demonstration. It is a collection of the actions at EU level to fund and promote research.
- Attack: Adoptive engineered T cell Targeting to Activate Cancer Killing, to improve T cell mediated immunotherapy to fight a broad range of cancer
- Clinigene: European Network for the Advancement of Clinical Gene Transfer and Therapy
- Consert: consortium of European research and clinical institutions cooperating to develop gene therapy for inherited diseases
- EPI-vector consortium to develop episomal vectors as gene delivery systems for therapeutic application
- GIANT: Gene Therapy, an integrated approach to neoplastic treatment, gene therapy for the treatment of prostate cancer
- Improved precision of Cystic Fibrosis therapy, a project investigating a new approach to the gene therapy of cystic fibrosis
- Tumor-Host Genomics, a concerted effort to understand tumor-host interactions, and to identify novel therapeutic targets
Info Research Centers
Overview of research institutes, centers and universities involved in pre-clinical and clinical gene therapy research:
Check here also the European Union Framework Programme Six (FP6) Integrated Projects, such as Attack, Clinigene, Consert and GIANT.
See also the European Union Framework Programme Seven (FP7) Integrated Projects.
Your Research Institute not listed? Click here to suggest
Like to work for a research center? Find here the perfect job in gene therapy.
US & Canada | |
Europe | |
Australia |
Check here also the European Union Framework Programme Six (FP6) Integrated Projects, such as Attack, Clinigene, Consert and GIANT.
See also the European Union Framework Programme Seven (FP7) Integrated Projects.
Your Research Institute not listed? Click here to suggest
Like to work for a research center? Find here the perfect job in gene therapy.
Gene Therapy News
- FDA Approves First Gene Therapy to Treat Children with Metachromatic Leukodystrophy - JD Supra
Fri, 29 Mar 2024 02:46:5 GMT - RGX-314 Gene Therapy for nAMD Well-Tolerated in Phase 1/2a Study - MD Magazine
Thu, 28 Mar 2024 23:12:1 GMT - Nanoscope targets FDA approval following positive gene therapy trial results - Longevity.Technology
Thu, 28 Mar 2024 19:17:3 GMT - Cell And Gene Therapy Manufacturing Services Market Set To Grow At A Rate Of More Than 16% Driven By Rising ... - GlobeNewswire
Thu, 28 Mar 2024 16:31:4 GMT - Cell And Gene Therapy CDMO Market Size to Reach USD 69.11 Bn by 2033 - BioSpace
Thu, 28 Mar 2024 16:06:0 GMT - Trial will test gene therapy for limb-girdle muscular dystrophy type - Muscular Dystrophy News
Thu, 28 Mar 2024 15:27:2 GMT - Cell therapy weekly: Clinical Trial Application Approval for Muscular Dystrophy Gene Therapy - RegMedNet
Thu, 28 Mar 2024 13:58:0 GMT - REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III - Genetic Engineering & Biotechnology News
Thu, 28 Mar 2024 12:05:1 GMT - Robots and AI: The Future of Cell and Gene Therapy Manufacturing - Genetic Engineering & Biotechnology News
Wed, 27 Mar 2024 17:00:2 GMT - Gene therapy offers hope for giant axonal neuropathy patients - UT Southwestern
Wed, 27 Mar 2024 16:52:2 GMT - Gene Therapy, DNA's Past, RNA's Future: Early History - Forbes
Wed, 27 Mar 2024 16:20:5 GMT - Nanoscope Claims Phase II Win for Gene Therapy After Changing Primary Endpoint - BioSpace
Wed, 27 Mar 2024 16:18:4 GMT - Atamyo's gene therapy for LGMD2C/R5 cleared to enter clinic in Europe - BioWorld Online
Wed, 27 Mar 2024 14:00:0 GMT - Atamyo obtains clearance for muscular dystrophy gene therapy trial in Europe - Clinical Trials Arena
Wed, 27 Mar 2024 12:26:4 GMT - Gene therapy maker bluebird to revise financials after accounting errors - Reuters
Tue, 26 Mar 2024 15:55:0 GMT